Choline Reset Aging Mitochondria in 2 Days; NMN Doubled NAD+ [Best Read]
Plus exercise that cut 7 months off GrimAge, senolytics clearing aged cells in 11 days, and klotho's 20% lifespan boost
In my work as a Silicon Valley based startup executive and longevity researcher, I track the gap between what the labs are publishing and what’s actually worth adding to your protocol. Here’s what stood out this week — with the numbers that matter.
Restoring one membrane lipid rebuilt aging mitochondria in just 2 days [Nature Communications]
A team at the Leibniz Institute on Aging found that phosphatidylcholine — one of the most abundant lipids in cell membranes — naturally declines with age, fragmenting the mitochondrial network and starving cells of flexible energy. When they fed aged C. elegans phosphatidylcholine or its precursor choline, youthful mitochondrial structure returned within just two days, and the fix still worked when started in middle or advanced age. Human lipidomic data showed the steepest phosphatidylcholine drop in women around menopause — the same window when many report energy crashes and persistent fatigue. For your protocol, it is an early but striking case that a cheap dietary nutrient like choline may target a hallmark of aging directly rather than just masking symptoms.
1 g of NMN or NR doubled blood NAD+ in 14 days; nicotinamide did nothing [Nature Metabolism]
Nestlé Health Science researchers ran the first head-to-head human comparison of three NAD+ precursors in 65 healthy adults (average age 34.7), dosing 1 g NR, 1 g NMN, or 0.5 g nicotinamide daily for two weeks. NR and NMN each raised whole-blood NAD+ roughly two-fold, while nicotinamide produced only a transient four-hour spike and no sustained gain. The data also exposed the mechanism: gut microbes convert NR and NMN into nicotinic acid, and both precursors boosted short-chain fatty acids tied to lower inflammation. The practical takeaway — if you supplement for NAD+, NR and NMN look interchangeable and plain nicotinamide is the weak link.
Six months of cycling raised VO2 max 20% and cut GrimAge by 7.4 months [GeroScience]
In a six-month endurance-training study, participants improved VO2 max by 20% (P<0.001), and their GrimAge epigenetic clock dropped 7.44 months relative to its expected trajectory (P=0.012). The fitness gain directly predicted the slowdown in biological aging (R²=0.27), and cardiorespiratory fitness — VO2 peak specifically — tracked epigenetic age more tightly than grip strength or leg power. This is some of the cleanest human evidence that aerobic capacity does not just correlate with longevity but actually moves the epigenetic needle. For your protocol: zone 2 base work plus VO2-max intervals remain the highest-leverage, lowest-cost longevity intervention available.
Dasatinib plus quercetin cleared senescent cells from human fat in 11 days [EBioMedicine]
A short course of the senolytic combination dasatinib plus quercetin reduced senescent-cell burden in human adipose tissue within just 11 days, lowering circulating SASP inflammatory factors including IL-1α, IL-6, and MMPs. In a separate trial in idiopathic pulmonary fibrosis patients, the same intermittent protocol improved measured physical function such as six-minute walk distance. Through 2026 the approach is expanding into trials for kidney disease, frailty, osteoarthritis, and early Alzheimer’s. The biohacker takeaway: senolytics are dosed in short pulses, not daily, and the human senescent-cell-clearance signal is now real — though hard healthspan endpoints are still being established.
A single klotho gene-therapy shot extended mouse lifespan 19.7% [SciTechDaily]
Researchers delivered the longevity protein klotho to 12-month-old mice (roughly age 40 in humans) and saw median lifespan rise 15–20%, peaking at 19.7%, alongside reduced muscle fibrosis, more satellite-cell proliferation, and better bone health — from a single one-time dose. Klotho levels fall with age, and this target is unusual in improving both cognitive and physical aging at once. A human proof-of-concept klotho trial completed in spring 2026, with broader development now underway. The caveat for biohackers: mouse lifespan wins rarely translate cleanly, so treat klotho as a promising target to watch, not a protocol item yet.
1000 mg urolithin A outperformed lower doses on muscle and mitochondria [Clinical Review 2026]
Pooled placebo-controlled human data show that a 1000 mg daily dose of urolithin A (Mitopure) produces broader, more pronounced gains in mitochondrial gene expression, muscle strength, endurance, and immune markers than lower doses. Urolithin A, a gut metabolite of pomegranate and berry ellagic acid, works by triggering mitophagy — the clearing of damaged mitochondria — and earlier trials show measurable strength and exercise-recovery improvements in middle-aged and older adults. A new randomized trial (updated March 2026) is directly comparing 500 mg versus 1000 mg over six months. Practical note: many people do not produce meaningful urolithin A from food on their own, so supplementing may matter more here than diet.